CD39 transforming cancer therapy by modulating tumor microenvironment

被引：5

作者：

Xu, Suling ^{[1
]}

Ma, Yuhan ^{[1
]}

Jiang, Xinyu ^{[1
]}

Wang, Qingqing ^{[2
]}

Ma, Wenxue ^{[3
,4
]}

机构：

[1] Ningbo Univ, Affiliated Hosp 1, Dept Dermatol, Sch Med, Ningbo 315020, Zhejiang, Peoples R China

[2] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China

[3] Univ Calif San Diego, Sanford Stem Cell Inst, Dept Med, La Jolla, CA 92093 USA

[4] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

CANCER LETTERS | 2024年 / 597卷

关键词：

CD39; Tumor Microenvironment (TME); Immunoregulation; Angiogenesis; Metabolic reprogramming; Therapeutic targets; EXPRESSION; PROGNOSIS; SURFACE;

D O I：

10.1016/j.canlet.2024.217072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.

引用

页数：11

共 110 条

[91] Single-cell Transcriptomic Analysis Reveals an Immunosuppressive Network Between POSTN CAFs and ACKR1 ECs in TKI-resistant Lung Cancer [J].

Wang, Zhiyi ;

Yan, Ning ;

Sheng, Hailong ;

Xiao, Yazhi ;

Sun, Jingyuan ;

Cao, Chuanhui .

CANCER GENOMICS & PROTEOMICS, 2024, 21 (01) :65-78

[92]

Warren Michael C, 2023, Immunohorizons, V7, P366, DOI [10.4049/immunohorizons.2200089, 10.4049/immunohorizons.2200089]

[93]

Wei Z.R., 2021, Medicine in Drug Discovery, V11, P7

[94] High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma [J].

Wu, Jie ;

Wang, Yu-Chen ;

Xu, Wen-Hao ;

Luo, Wen-Jie ;

Wan, Fang-Ning ;

Zhang, Hai-Liang ;

Ye, Ding-Wei ;

Qu, Yuan-Yuan ;

Zhu, Yi-Ping .

ONCOTARGETS AND THERAPY, 2020, 13 :10453-10464

[95] CD39/CD73/A2AR pathway and cancer immunotherapy [J].

Xia, Chenglai ;

Yin, Shuanghong ;

To, Kenneth K. W. ;

Fu, Liwu .

MOLECULAR CANCER, 2023, 22 (01)

[96] The cancer metabolic reprogramming and immune response [J].

Xia, Longzheng ;

Oyang, Linda ;

Lin, Jinguan ;

Tan, Shiming ;

Han, Yaqian ;

Wu, Nayiyuan ;

Yi, Pin ;

Tang, Lu ;

Pan, Qing ;

Rao, Shan ;

Liang, Jiaxin ;

Tang, Yanyan ;

Su, Min ;

Luo, Xia ;

Yang, Yiqing ;

Shi, Yingrui ;

Wang, Hui ;

Zhou, Yujuan ;

Liao, Qianjin .

MOLECULAR CANCER, 2021, 20 (01)

[97] Neoantigens: promising targets for cancer therapy [J].

Xie, Na ;

Shen, Guobo ;

Gao, Wei ;

Huang, Zhao ;

Huang, Canhua ;

Fu, Li .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)

[98] The Immune Regulatory Role of Adenosine in the Tumor Microenvironment [J].

Xing, Jianlei ;

Zhang, Jinhua ;

Wang, Jinyan .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)

[99] Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy [J].

Xu, Suling ;

Wang, Qingqing ;

Ma, Wenxue .

CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 76 :12-21

[100] Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance [J].

Yao, Liqin ;

Wang, Qingqing ;

Ma, Wenxue .

CANCERS, 2023, 15 (24)

← 2 3 4 5 6 7 8 9 10 11 →